REPLIGEN CORP Deferred Other Tax Expense (Benefit)
REPLIGEN CORP (RGEN) reported Deferred Other Tax Expense (Benefit) of $767.00 thousand for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-07.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredOtherTaxExpenseBenefit · last filed 2015-03-17
- REPLIGEN CORP deferred other tax expense (benefit) for the quarter ending 2013-03-31 was $767.00K.
- REPLIGEN CORP deferred other tax expense (benefit) for the quarter ending 2012-12-31 was $3.02M.
- REPLIGEN CORP deferred other tax expense (benefit) for fiscal 2012 was $3.02M.
| Period end | Deferred Other Tax Expense (Benefit) 3 month | Deferred Other Tax Expense (Benefit) 6 month | Deferred Other Tax Expense (Benefit) 12 month |
|---|---|---|---|
| 2013-03-31 | $767.00K 10-Q · filed 2013-05-07 | $3.79M derived: sum of 2 quarters · filed 2014-11-07 | |
| 2012-12-31 | $3.02M 10-Q · filed 2014-11-07 | $3.02M 10-K · filed 2015-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |